MY182327A - Sugar moiety silyl ether derivative of 5-azacytidine - Google Patents

Sugar moiety silyl ether derivative of 5-azacytidine

Info

Publication number
MY182327A
MY182327A MYPI2018701923A MYPI2018701923A MY182327A MY 182327 A MY182327 A MY 182327A MY PI2018701923 A MYPI2018701923 A MY PI2018701923A MY PI2018701923 A MYPI2018701923 A MY PI2018701923A MY 182327 A MY182327 A MY 182327A
Authority
MY
Malaysia
Prior art keywords
azacytidine
formula
substituent
hydrogen atom
sugar moiety
Prior art date
Application number
MYPI2018701923A
Other languages
English (en)
Inventor
Magoichi Sako
Shinpei Sugiyama
Original Assignee
Ohara Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohara Pharmaceutical Co Ltd filed Critical Ohara Pharmaceutical Co Ltd
Publication of MY182327A publication Critical patent/MY182327A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12Triazine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MYPI2018701923A 2016-04-21 2016-07-27 Sugar moiety silyl ether derivative of 5-azacytidine MY182327A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016085145 2016-04-21
PCT/JP2016/065660 WO2017183215A1 (ja) 2016-04-21 2016-05-27 5-アザシチジン類の糖部シリルエーテル誘導体
PCT/JP2016/072010 WO2017183217A1 (ja) 2016-04-21 2016-07-27 5-アザシチジン類の糖部シリルエーテル誘導体

Publications (1)

Publication Number Publication Date
MY182327A true MY182327A (en) 2021-01-19

Family

ID=60115962

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018701923A MY182327A (en) 2016-04-21 2016-07-27 Sugar moiety silyl ether derivative of 5-azacytidine

Country Status (7)

Country Link
US (1) US9901641B2 (enExample)
EP (2) EP3252067B1 (enExample)
JP (2) JP6162349B1 (enExample)
KR (1) KR102579485B1 (enExample)
CN (1) CN108368148B (enExample)
MY (1) MY182327A (enExample)
WO (2) WO2017183215A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10227374B2 (en) * 2016-04-21 2019-03-12 Ohara Pharmaceutical Co., Ltd. Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety
JP6956937B2 (ja) * 2018-02-19 2021-11-02 大原薬品工業株式会社 Dnmt阻害剤の用途
JP7228169B2 (ja) * 2018-10-30 2023-02-24 大原薬品工業株式会社 医薬組成物
US12472196B2 (en) * 2019-09-26 2025-11-18 Ohara Pharmaceutical Co., Ltd. Use of DNMT inhibitor
WO2022031759A1 (en) * 2020-08-04 2022-02-10 Herophilus, Inc. Decitabine induced mecp2 expression and uses thereof
JP7519657B2 (ja) * 2021-02-23 2024-07-22 大原薬品工業株式会社 慢性骨髄性白血病幹細胞阻害剤
WO2025142803A1 (ja) * 2023-12-25 2025-07-03 大原薬品工業株式会社 Dnmt阻害剤の経口投与用の医薬組成物
WO2025263591A1 (ja) * 2024-06-21 2025-12-26 大原薬品工業株式会社 経口用dnmt阻害剤の結晶形態

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816619A (en) 1965-08-25 1974-06-11 Upjohn Co Ladakamycin and process for preparing same
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
AU2003302624A1 (en) * 2002-11-29 2004-06-23 Amedis Pharmaceuticals Ltd. Silicon compounds
GB0227906D0 (en) * 2002-11-29 2003-01-08 Amedis Pharm Ltd Compounds and their use
KR100897924B1 (ko) 2002-12-10 2009-05-18 엘지엔시스(주) 금융통합단말기 프린터부의 용지가이드 장치
KR100866399B1 (ko) 2002-12-10 2008-11-03 엘지엔시스(주) 매체자동지급기의 모듈부 스톱퍼장치
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN102010455B (zh) * 2009-09-05 2012-07-11 山东新时代药业有限公司 一种地西他滨的制备方法
JP6289361B2 (ja) * 2011-03-31 2018-03-07 セルジーン インターナショナル サルル 5−アザシチジンの合成
WO2013036846A2 (en) * 2011-09-09 2013-03-14 Koronis Pharmaceuticals, Incorporated N4 derivatives of deoxycytidine prodrugs
ES2746105T3 (es) * 2014-10-08 2020-03-04 Epigenetics Pharma Llc Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
KR101922702B1 (ko) 2016-05-10 2018-11-29 주식회사 씨엔제이 기판용 필름의 재활용 칩 제작방법 및 장치

Also Published As

Publication number Publication date
WO2017183215A1 (ja) 2017-10-26
EP3543249A1 (en) 2019-09-25
CN108368148B (zh) 2021-11-05
WO2017183217A1 (ja) 2017-10-26
JPWO2017183217A1 (ja) 2018-04-26
JP6162349B1 (ja) 2017-07-12
EP3252067A4 (en) 2017-12-06
KR102579485B1 (ko) 2023-09-20
EP3252067A1 (en) 2017-12-06
JP2017197539A (ja) 2017-11-02
EP3252067B1 (en) 2019-05-29
US20170304337A1 (en) 2017-10-26
CN108368148A (zh) 2018-08-03
US9901641B2 (en) 2018-02-27
KR20180134835A (ko) 2018-12-19

Similar Documents

Publication Publication Date Title
PH12020551305A1 (en) Pharmaceutical Compounds
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
CY1118572T1 (el) Παραγωγο κυκλοαλκανιου
MX2010006421A (es) Compuestos organicos.
PH12018502633B1 (en) Substituted pyridines as inhibitors of dnmt1
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
GEP20227433B (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
MX2016006919A (es) Nucleotidos para el tratamiento de cancer de higado.
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
PH12014501719A1 (en) Pyridone derivatives
MX2010009922A (es) Activadores de piridazinona glucocinasa.
EA201001772A1 (ru) Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
MX2012013274A (es) Novedosos derivados de la pirimidina.
IL204437A (en) History of aryl cyclic profile and their use
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
CA2920410C (en) Thienopiperidine derivative and use thereof
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
HK1217295A1 (zh) 4'-疊氮基,3'-脫氧基-3'-氟取代的核苷衍生物